Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit

5AM Venture Management sold its entire 170,000-share stake in Praxis Precision Medicines (PRAX) in Q4, cutting the quarter-end position value by $9.01 million and fully exiting a position that had been ~3.3% of the fund's AUM. PRAX trades at $291.70 with an $8.1B market cap, a TTM net loss of $303.3M, roughly $926M cash on hand and an additional $621M raised in early 2026 (runway into 2028). Shares have surged nearly 700% over the past year but are ~30% below the quarter-end high, so the sale appears to reflect growing execution risk rather than a fundamental collapse; the $9.01M move is modest versus market cap but notable as a signal from an active biotech investor.

Analysis

5AM’s full exit materially widens the free float for an already high-volatility small-cap biotech and removes a marginal but identifiable source of buy-side price support ahead of binary clinical and regulatory catalysts. With fewer concentrated holders, short-term spreads and option-implied vols are likely to rise; that makes immediate directional exposure more about event-timing than secular thesis — days-to-weeks around readouts will dominate returns.

The company’s valuation now trades more explicitly as an options-on-outcomes story: cash runway reduces near-term financing risk, so upside requires clean clinical/NDA execution and commercialization cadence rather than balance-sheet relief. That shifts the payoff distribution: cluster of positive readouts could deliver multi-bagger moves within 6–18 months, while a single negative outcome could compress value by 40–70% in days.

Second-order beneficiaries include CROs, specialty suppliers and potential large-pharma acquirers; lower insider/fund concentration increases the likelihood of opportunistic licensing or partnering conversations if upcoming readouts are mixed. Conversely, CRO and supply-chain capacity could be reallocated away from lower-probability programs if multiple small biotechs simultaneously pull back, creating spot bottlenecks for peers with tightly scheduled studies.

For portfolio construction the immediate regime is higher idiosyncratic volatility and event risk; treat the name like a binary with skewed tail risk rather than a linear growth holding. Liquidity and implied volatility mean options structures and pairs will typically deliver a better risk/reward than naked equity exposure over the next 3–12 months.

Key Decisions for Investors

• Hedge-first long exposure: if bullish on upcoming NDAs, buy the stock only paired with a 6–12 month protective put (cost ~3–6% of notional). Position size: limit to 1–2% of fund NAV; R/R: downside capped to put cost + 10% realized slippage, upside target 50–100% if approvals and early commercial traction materialize within 12 months.
• Event hedge (cheap tail insurance): buy a 3-month put spread ~30%/15% OTM to limit premium outlay (~1–2% of notional) ahead of the next clinical/NDA milestone. This creates ~4–6x payoff if shares drop >30% in weeks — low carry, high asymmetry for short-term downside protection.
• Pair trade for de-risked exposure: short PRAX (1x) vs long a diversified biotech basket/ETF (1x) or a larger CNS peer to neutralize sector beta. Timeframe 3–9 months — expected edge if idiosyncratic execution risk re-prices; target capture of 20–40% relative move with stop-loss at 15% adverse dispersion.
• Reallocate realized gains into sentiment leaders outside biotech: redeploy 50–100 bps into structural growth names with positive skew (e.g., NVDA) on any >8% pullback over a 3–6 month window as a portfolio-level hedge against concentrated binary biotech risk. Risk/reward: NVDA provides beta to risk-on flows while reducing single-name binary exposure.